The company is so far trading up since yesterday’s close of $313.56. It is trading at $315.11 just a bit higher than $309.48, the 50 day moving average and which is a tad above the 200 day moving average of $257.26. The 50 day moving average was up by +1.86% whereas the 200 day moving average was up $57.98 or +22.54%.
Here is the rundown on market activity for C.R. Bard, Inc. Common Stock (NYSE:BCR). Frank Jr Lupisella, VP let go of $1,101,088 worth of shares at an average price of $304.00 on Mon the 24th. Lupisella now owns $3,082,162 of stock per an SEC filing yesterday. Jim C. Beasley, Group President disclosed the sale of 4,390 shares. The shares were purchased at an average price of $245.00. Beasley now owns $5,447,575 of the stock per the Form 4 SEC filing.
Sr VP Christopher S. Holland disclosed the sale of 618 shares of (BCR). The shares were sold on February 14th for an average price of $240.53. The Sr VP now owns $6,475,652 of the stock according to the SEC filing.
C. R. Bard, Inc. (Bard), incorporated in 1923, is involved in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. The Company sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company reports its sales in four product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. As of December 31, 2016, the Company, through its subsidiaries, marketed its products to customers in over 100 countries outside the United States. The Business’s principal international markets are in Europe, Japan and China..
The following firms have also recently changed their position in BCR. Shamrock Asset Management LLC divested its position by selling 6 shares a decrease of 7.3% in the quarter. Shamrock Asset Management LLC currently owns 76 shares worth $19,000. The total value of its holdings increased 5.6%. As of quarter end Mackenzie Financial Corp had acquired a total of 218,478 shares growing its stake by 1,323.0%. The value of the company’s investment in C.R. Bard, Inc. Common Stock went from $3,883,000 to $58,405,000 increasing 1,404.1% for the reporting period.
As of the end of the quarter Hm Payson & Co had bought 95 shares growing its holdings by 9.4%. The value of the total investment in C.R. Bard, Inc. Common Stock increased from $227,000 to $275,000 a change of 21.1% since the last quarter. As of quarter end Proficio Capital Partners LLC had acquired 5 shares growing its position 21.7%. The value in dollars went from $5,000 to $9,000 a change of $4,000 quarter to quarter.
On December 12 the stock rating was upgraded from “” to “Outperform” and a price target of $245.00 was set in a report from BMO Capital. On September 16 the company was rated “Outperform” in a report from Wells Fargo a boost from the previous “Market Perform” rating.
Evercore ISI Group issued its first research report on the stock with an initial rating of “Buy” and setting a price target of $235.00. On July 27 JP Morgan left the stock rating at “Equalweight” but moved up the price target from $178.00 to $235.00.
July 27 investment analysts at Jefferies maintained a company rating of “Equalweight” and raised the price target to $235.00 from $170.00. On July 27 Citigroup kept the stock rating at “Equalweight” but raised the price target from $220.00 to $235.00.
Additionally the company announced a dividend to be paid on Friday August 4th, 2017. The dividend payment will be $0.260 per share for the quarter which comes to $1.04 on an annualized basis. The dividend yield will be $0.33. The ex-dividend date will be on Thursday the 27th of April 2017.
The company currently has a P/E ratio of 40.12 and market capitalization is 22.83B. In the last earnings report the EPS was $7.86 and is estimated to be $11.78 for the current year with 72,417,000 shares outstanding. Next quarter’s EPS is forecasted to be $2.99 with next year’s EPS projected to be $12.91.